



Hawley et al Figure S1

A) Coomassie Blue staining of purified rat liver and human  $\alpha 2\beta 2\gamma 1$  complexes




B) Western blotting of purified rat liver (R) and human  $\alpha 2\beta 2\gamma 1$  (H) complexes




**Figure S1:** Analysis by Coomassie Blue staining (A) and Western blotting (B) of the purified preparations of rat liver and human ( $\alpha 2\beta 2\gamma 1$ ) AMPK complexes used in this study. The markers used (lane M) were SeeBlue Plus2 Prestained Protein Standards (ThermoFisher Scientific), and the molecular masses are those given by the manufacturer for the gel system used. The AMPK subunit isoforms labelled in (A) were identified by reference to the Western blots in (B). Note from the Western blots in (B) that rat  $\beta 1$ ,  $\beta 2$  and  $\gamma 1$  co-migrate and are therefore not resolved in the Coomassie Blue-stained gel in (A).

## Hawley et al Figure S2


A)  $\gamma 1$  mutants co-purify with  $\alpha 2$  and  $\beta 2$  as stable heterotrimers



B)  $\gamma 1$  mutants all activated by CaMKK2




C)  $\gamma 1$  mutants all activated by LKB1



**Figure S2:** (A) Analysis by SDS-PAGE and Coomassie Blue staining of purified bacterially expressed human  $\alpha 2\beta 2\gamma 1$  complexes, either WT or with mutations affecting CBS1, CBS3 or CBS4; (B) activation of WT or CBS mutants using increasing concentrations of CaMKK2; (C) activation of WT or CBS mutants using increasing concentrations of LKB1:STRAD $\alpha$ :MO25 $\alpha$  complex. For (A), the complexes had been purified using the (His) $_6$  tag on the  $\alpha 2$  subunit; the gel shows that stable  $\alpha\beta\gamma$  complexes are formed with the WT and each mutant. (B) and (C) show that the mutations do not affect phosphorylation and activation by either upstream kinase.

**Fig. 5B/6B:** uncropped blots (promotion/protection of phosphorylation/dephosphorylation)



**NOTES:**

- the molecular mass markers used (in lanes designated M) were SeeBlue Plus2 prestained protein standards (Cat. no. LC5925, ThermoFisher Scientific)
- the molecular masses given for the markers are those quoted by the manufacturer's for the gel system used

Enzyme	Activator	ATP (mM)	Basal $\pm$ SD (CI) (nmol/min/mg)	Activation (fold)	EC <sub>50</sub> ( $\mu$ M)	IC <sub>50</sub> (mM)	IC <sub>50</sub> /EC <sub>50</sub>
Rat liver	AMP	0.2	121 $\pm$ 4	2.9 (2.8-3.0)	6.4 (5.4-7.5)	1.7 (1.6-2.0)	270
Rat liver	AMP	1.0	129 $\pm$ 4	2.8 (2.7-2.9)	14 (12-16)	6.9 (6.1-7.8)	490
Rat liver	AMP	5.0	96 $\pm$ 4	3.7 (3.5-3.8)	36 (28-46)	17 (13-23)	470
Rat liver	ADP	0.2	161 $\pm$ 7	none*	-	0.40 (0.36-0.44)	-
Rat liver	ADP	1.0	147 $\pm$ 7	2.4 (1.8-??)	122 (65-??)	0.69 (0.61-0.78)	5.7
Rat liver	ADP	5.0	123 $\pm$ 1	2.0 (1.7-2.8)	220 (120-440)	4.0 (2.7-5.4)	18
$\alpha$ 2-KD	AMP	0.2	1020 (990-1040)	none*	-	2.2 (1.8-2.7)	-
$\alpha$ 2-KD	AMP	1.0	2410 (2360-2460)	none*	-	5.4 (4.5-6.5)	-
$\alpha$ 2-KD	AMP	5.0	2300 (2260-2340)	none*	-	13.4 (11.1-16.4)	-
$\alpha$ 2-KD	ADP	0.2	1180 (1150-1210)	none*	-	0.67 (0.59-0.77)	-
$\alpha$ 2-KD	ADP	1.0	2600 (2550-2660)	none*	-	1.6 (1.4-1.9)	-
$\alpha$ 2-KD	ADP	5.0	2630 (2570-2690)	none*	-	3.5 (3.0-4.1)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 WT	AMP	0.2	1558 $\pm$ 36	2.6 (2.5-2.6)	1.0 (0.8-1.2)	2.6 (2.3-2.9)	2600
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 WT	AMP	5.0	1363 $\pm$ 40	3.0 (2.9-3.1)	19 (15-24)	52 (41-68)	2700
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 WT	ADP	0.2	1448 $\pm$ 15	none*	-	2.6 (??-??)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 WT	ADP	5.0	1334 $\pm$ 81	9.9 (2.8-??)	785 (321-??)	1.2 (??-2.5)	1.5
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS1	AMP	0.2	1590 $\pm$ 47	2.4 (2.3-2.4)	1.6 (1.3-1.9)	3.4 (3.1-3.8)	2100
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS1	AMP	5.0	2219 $\pm$ 154	3.0 (2.9-3.1)	19 (15-24)	52 (41-68)	2700
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS1	ADP	0.2	1879 $\pm$ 67	none*	-	1.0 (0.45-??)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS1	ADP	5.0	1880 $\pm$ 106	none*	-	1.2 (??-2.5)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS3	AMP	0.2	1402 $\pm$ 0	1.2 (1.1-1.2)	2.9 (0.7-5.1)	6.1 (5.0-7.4)	2100
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS3	AMP	5.0	1774 $\pm$ 95	2.3 (2.1-2.7)	370 (220-650)	40 (27-60)	110
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS3	ADP	0.2	1629 $\pm$ 43	none*	-	0.5 (0.3-??)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS3	ADP	5.0	1363 $\pm$ 14	-	-	7.6 (4.5-??)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS4	AMP	0.2	1539 $\pm$ 8	2.1 (2.0-2.1)	38 (30-49)	3.3 (2.9-3.8)	87
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS4	AMP	5.0	2047 $\pm$ 59	2.1 (1.9-2.4)	280 (160-500)	28 (20-41)	100
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS4	ADP	0.2	1766 $\pm$ 23	none*	-	0.78 (0.35-??)	-
$\alpha$ 2 $\beta$ 2 $\gamma$ 1 CBS4	ADP	5.0	1459 $\pm$ 69	none*	-	31 (??-??)	-

**Table S1: Summary of parameters estimated from data in Figures 1, 3 and 4.** These parameters were used to draw the curves in those Figures, using the equations given in Figure legends. Figures in parentheses indicate 95% confidence intervals for that parameter estimated by curve fitting, while the figures after “ $\pm$ ” symbols are standard deviations calculated from the individual basal activities. “??” indicates that that confidence interval could not be reliably determined. The entry “none\*” indicates that the activation was not significant and parameters relevant to activation could not be reliably determined.